Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Dan Hung Barouch, M.D.

Co-Author

This page shows the publications co-authored by Dan Barouch and Kathryn Stephenson.
Connection Strength

13.454
  1. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat Med. 2021 10; 27(10):1718-1724.
    View in: PubMed
    Score: 0.935
  2. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021 04 20; 325(15):1535-1544.
    View in: PubMed
    Score: 0.905
  3. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2020 09; 20(9):1061-1070.
    View in: PubMed
    Score: 0.847
  4. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. Annu Rev Immunol. 2020 04 26; 38:673-703.
    View in: PubMed
    Score: 0.846
  5. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22). Lancet HIV. 2020 06; 7(6):e410-e421.
    View in: PubMed
    Score: 0.835
  6. First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. PLoS One. 2018; 13(11):e0205139.
    View in: PubMed
    Score: 0.765
  7. New concepts in HIV-1 vaccine development. Curr Opin Immunol. 2016 08; 41:39-46.
    View in: PubMed
    Score: 0.645
  8. Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy. Open Forum Infect Dis. 2016 Apr; 3(2):ofw100.
    View in: PubMed
    Score: 0.644
  9. Broadly Neutralizing Antibodies for HIV Eradication. Curr HIV/AIDS Rep. 2016 Feb; 13(1):31-7.
    View in: PubMed
    Score: 0.631
  10. Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. J Immunol Methods. 2015 Jan; 416:105-23.
    View in: PubMed
    Score: 0.580
  11. A global approach to HIV-1 vaccine development. Immunol Rev. 2013 Jul; 254(1):295-304.
    View in: PubMed
    Score: 0.527
  12. Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. J Virol. 2012 Nov; 86(21):11434-40.
    View in: PubMed
    Score: 0.496
  13. Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys. J Virol. 2012 Sep; 86(18):9583-9.
    View in: PubMed
    Score: 0.492
  14. Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials. J Infect Dis. 2012 Jun 15; 205(12):1806-10.
    View in: PubMed
    Score: 0.484
  15. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat Med. 2022 06; 28(6):1288-1296.
    View in: PubMed
    Score: 0.244
  16. Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters. NPJ Vaccines. 2022 Jan 10; 7(1):2.
    View in: PubMed
    Score: 0.238
  17. Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination. N Engl J Med. 2021 09 02; 385(10):951-953.
    View in: PubMed
    Score: 0.230
  18. Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19. medRxiv. 2021 Jul 07.
    View in: PubMed
    Score: 0.230
  19. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021 08; 596(7871):268-272.
    View in: PubMed
    Score: 0.228
  20. A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine. Ann Intern Med. 2021 05; 174(5):585-594.
    View in: PubMed
    Score: 0.224
  21. Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. Cell. 2020 11 25; 183(5):1354-1366.e13.
    View in: PubMed
    Score: 0.218
  22. Zika virus vaccines. Nat Rev Microbiol. 2018 10; 16(10):594-600.
    View in: PubMed
    Score: 0.190
  23. Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys. J Virol. 2018 08 01; 92(15).
    View in: PubMed
    Score: 0.187
  24. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018 07 21; 392(10143):232-243.
    View in: PubMed
    Score: 0.187
  25. Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. J Virol. 2018 07 01; 92(13).
    View in: PubMed
    Score: 0.186
  26. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature. 2016 12 08; 540(7632):284-287.
    View in: PubMed
    Score: 0.166
  27. Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4+ T cell responses that impair CD8+ T cell function. Sci Immunol. 2016 Nov; 1(5).
    View in: PubMed
    Score: 0.166
  28. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science. 2016 09 09; 353(6304):1129-32.
    View in: PubMed
    Score: 0.163
  29. Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization. Clin Vaccine Immunol. 2015 Nov; 22(11):1166-75.
    View in: PubMed
    Score: 0.154
  30. Common features of mucosal and peripheral antibody responses elicited by candidate HIV-1 vaccines in rhesus monkeys. J Virol. 2014 Nov; 88(22):13510-5.
    View in: PubMed
    Score: 0.143
  31. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013 Nov 14; 503(7475):224-8.
    View in: PubMed
    Score: 0.135
  32. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013 Oct 24; 155(3):531-9.
    View in: PubMed
    Score: 0.135
  33. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021 05 13; 384(19):1824-1835.
    View in: PubMed
    Score: 0.056
  34. HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. Cell Rep. 2020 12 15; 33(11):108502.
    View in: PubMed
    Score: 0.055
  35. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nat Med. 2020 02; 26(2):228-235.
    View in: PubMed
    Score: 0.052
  36. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host Microbe. 2019 08 14; 26(2):296.
    View in: PubMed
    Score: 0.050
  37. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV. 2019 04; 6(4):e259-e268.
    View in: PubMed
    Score: 0.049
  38. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host Microbe. 2019 01 09; 25(1):59-72.e8.
    View in: PubMed
    Score: 0.048
  39. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. J Infect Dis. 2018 07 13; 218(4):633-644.
    View in: PubMed
    Score: 0.047
  40. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2018 02 10; 391(10120):563-571.
    View in: PubMed
    Score: 0.045
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.